Skip to content
lifestyle.gooddecisions.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Insilico Medicine
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
June 17, 2026
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
May 20, 2026
Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
April 28, 2026
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
April 24, 2026
Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
April 22, 2026
Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
April 21, 2026
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health
March 24, 2026
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
February 25, 2026
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
February 3, 2026
←
Previous Page
1
2
3